Item 7.01. Regulation FD Disclosure.

Encompass Health Corporation (the "Company" or "Encompass Health") will participate in the Mizuho Securities USA LLC "CEO Insight Series" on November 14, 2022. Encompass Health President and Chief Executive Officer, Mark Tarr, will be responding to investor questions on Monday, November 14th at 10:30 a.m. CT.

The Company reiterates as of the date hereof its guidance and related assumptions previously reported in its Current Report on Form 8-K, dated October 26, 2022, and during the Company's earnings conference call held on October 27, 2022. Accordingly, the Company continues to expect the following full-year 2022 ranges:

•Net operating revenues of $4,320 million to $4,350 million;

•Adjusted EBITDA of $800 million to $820 million; and

•Adjusted earnings per share from continuing operations attributable to Encompass Health of $2.71 to $2.86.

The information contained herein is being furnished pursuant to Item 7.01 of Form 8-K, "Regulation FD Disclosure." This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein.

Note Regarding Presentation of Non-GAAP Financial Measures

Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees-accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP.

However, the following reasonably estimable GAAP measures for 2022 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:

•Interest expense and amortization of debt discounts and fees - estimate of $150 million to $160 million

•Amortization of debt-related items - approximately $10 million

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses